Anchor Capital Advisors LLC cut its stake in shares of Pfizer, Inc. (NYSE:PFE) by 2.6% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 783,888 shares of the biopharmaceutical company’s stock after selling 20,529 shares during the period. Anchor Capital Advisors LLC’s holdings in Pfizer were worth $26,331,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. D. Scott Neal Inc. boosted its position in Pfizer by 19.3% during the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 504 shares during the period. Franklin Parlapiano Turner & Welch LLC purchased a new stake in Pfizer during the 1st quarter worth $121,000. Cascade Investment Advisors Inc. boosted its position in Pfizer by 89.1% during the 2nd quarter. Cascade Investment Advisors Inc. now owns 4,669 shares of the biopharmaceutical company’s stock worth $157,000 after purchasing an additional 2,200 shares during the period. Patten Group Inc. boosted its position in Pfizer by 5.1% during the 1st quarter. Patten Group Inc. now owns 5,181 shares of the biopharmaceutical company’s stock worth $177,000 after purchasing an additional 252 shares during the period. Finally, Acropolis Investment Management LLC boosted its position in Pfizer by 6.7% during the 2nd quarter. Acropolis Investment Management LLC now owns 5,603 shares of the biopharmaceutical company’s stock worth $188,000 after purchasing an additional 352 shares during the period. 69.01% of the stock is owned by institutional investors.

In other Pfizer news, insider Sally Susman sold 38,230 shares of the firm’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $35.00, for a total value of $1,338,050.00. Following the sale, the insider now directly owns 145,649 shares in the company, valued at approximately $5,097,715. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Ian C. Read sold 96,950 shares of the firm’s stock in a transaction on Friday, August 4th. The stock was sold at an average price of $34.00, for a total transaction of $3,296,300.00. The disclosure for this sale can be found here. Insiders sold a total of 464,521 shares of company stock worth $15,813,961 over the last 90 days. Company insiders own 0.06% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Anchor Capital Advisors LLC Lowers Stake in Pfizer, Inc. (PFE)” was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark law. The original version of this story can be accessed at https://theolympiareport.com/2017/10/31/anchor-capital-advisors-llc-lowers-stake-in-pfizer-inc-pfe.html.

Shares of Pfizer, Inc. (PFE) opened at 35.15 on Tuesday. The firm has a market cap of $209.05 billion, a price-to-earnings ratio of 25.71 and a beta of 1.00. Pfizer, Inc. has a 52 week low of $29.83 and a 52 week high of $36.78. The stock has a 50 day moving average of $35.84 and a 200-day moving average of $33.91.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.02. The company had revenue of $12.90 billion for the quarter, compared to analyst estimates of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The business’s quarterly revenue was down 1.9% on a year-over-year basis. During the same period last year, the business posted $0.64 EPS. Equities research analysts expect that Pfizer, Inc. will post $2.56 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Friday, November 10th will be given a $0.32 dividend. The ex-dividend date is Thursday, November 9th. This represents a $1.28 annualized dividend and a yield of 3.64%. Pfizer’s dividend payout ratio is 94.12%.

A number of brokerages recently weighed in on PFE. Jefferies Group LLC set a $39.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a research report on Thursday, October 26th. BMO Capital Markets reaffirmed a “buy” rating and set a $39.00 price target (up from $37.00) on shares of Pfizer in a research report on Thursday, October 19th. Deutsche Bank AG set a $38.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research report on Wednesday, October 11th. Zacks Investment Research cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th. Finally, Barclays PLC set a $38.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research report on Wednesday, October 11th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $38.32.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.